The complaint, filed by the law firm Bronstein, Gewirtz & Grossman, LLC, alleges that Chemours executives overstated aftermarket demand for Opteon products. According to the filing, the company had engaged in aggressive overselling during the previous fiscal year, causing a subsequent decline in demand that was not transparently communicated to the market. Consequently, the firm argues that the financial guidance provided by Chemours for the 2026 fiscal year was fundamentally unreliable.

Shareholders who suffered financial losses have until December 7, 2026, to petition the court to be appointed as lead plaintiff. While the firm operates on a contingency fee basis, meaning legal expenses are only recovered if the suit is successful, participation as a lead plaintiff is not a requirement for individual investors to share in any potential settlement. Interested parties can review the complaint or contact attorneys Peretz Bronstein or Nathan Miller for further details regarding the case.